{"id":8124,"date":"2020-02-03T10:25:15","date_gmt":"2020-02-03T18:25:15","guid":{"rendered":"https:\/\/www.hmc.edu\/about-hmc\/?p=8124"},"modified":"2024-03-27T09:59:27","modified_gmt":"2024-03-27T16:59:27","slug":"researchers-employ-mathematical-modeling-to-study-tumor-immune-dynamics","status":"publish","type":"post","link":"https:\/\/www.hmc.edu\/about\/2020\/02\/03\/researchers-employ-mathematical-modeling-to-study-tumor-immune-dynamics\/","title":{"rendered":"Researchers Employ Mathematical Modeling to Study Tumor-immune Dynamics"},"content":{"rendered":"\n

A collaboration between Lisette de Pillis, Norman F. Sprague Jr. Professor of Life Sciences and Professor of Mathematics at Harvey Mudd College, and international colleagues in mathematics and in experimental biology has culminated in the publication of \u201cMesenchymal stem cells (MSCs) used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy<\/a>\u201d in Nature.<\/em><\/p>\n\n\n\n

The collaboration began in 2015, when de Pillis\u2019s work with mathematical modeling of immune dynamics and interaction with tumor growth led her to present at an American Institute of Mathematics workshop on tumor-immune dynamics<\/a>.<\/p>\n\n\n\n

\u201cAt this workshop, our core group of collaborators began brainstorming about how we might better understand some of the challenges involved with delivering oncolytic virus (OV) to a tumor site,\u201d de Pillis says. \u201cThe team was multinational and multidisciplinary\u2014bioengineers and mathematicians based in the U.K., South Africa, South Korea and the U.S. working together.\u201d<\/p>\n\n\n\n

De Pillis and her colleagues constructed a mathematical model to help them understand under what conditions mesenchymal stem cell-oncolytic viral (MSC-OV) therapy can be effective. Current research is investigating MSCs loaded with oncolytic viruses as a new method of treating advanced\/metastatic tumors and enhancement of virotherapy. \u201cTo address the critical question of how MSCs loaded with oncolytic viruses affect virotherapy outcomes and tumor growth patterns in a tumor microenvironment, we developed and analyzed an integrated mathematical-experimental model,\u201d de Pillis says.<\/p>\n\n\n\n

MSC-OV therapy design must take into account the behaviors both of the MSCs and the OVs, de Pillis explains. \u201cOVs have the ability to target and attack cancer cells in a way that does not damage healthy cells. The kind of virus our collaborators are experimenting with is an oncolytic adenovirus, which is a genetically modified virus that was approved in China in 2005 for the treatment of head and neck cancer. OVs are able not only to destroy tumor cells, but are also able to stimulate an anti-tumor immune response. The immune stimulation can be both beneficial (extra tumor-killing activity) and precisely the thing that stops the OV therapy from being able to work. Why? Once injected into the individual\u2014because the OV does stimulate an immune response\u2014that very response often ends up clearing out the virus before it ever makes it to the tumor site. So we need a way to ferry the virus to the tumor site and to protect the virus until it can reach its goal.\u201d<\/p>\n\n\n\n

There\u2019s an ongoing debate as to the usefulness of MSCs, de Pillis says, because they have the potential either to promote or to suppress tumor growth. However, because they are cells that have the ability to travel directly to tumor sites, they are potentially very useful vehicles for delivering anti-cancer agents effectively. \u201cWe can deliver the OV by loading it into an MSC: the MSC acts as the boat that ferries the virus to its destination, and potentially protects the virus from immune attack on the journey.\u201d<\/p>\n\n\n\n

The mathematical model developed in this research can help to quantitatively predict the consequences of using MSCs for delivering the OV within an individual. \u201cThe model revealed a surprising and counter-intuitive result: Using tumor-promoting MSCs to carry the oncolytic virus to the target (the tumor cells) is not only beneficial, but necessary if we are to control tumor growth,\u201d de Pillis says. \u201cThis model outcome has also been confirmed through laboratory experiments.\u201d<\/p>\n\n\n\n

De Pillis and her colleagues expect to continue working together and are discussing what they want to focus on next. \u201cWe have been working on aspects of this problem for a few years now, and we are all very excited that this last publication was accepted to Nature,<\/em>\u201d de Pillis says. \u201cNew discoveries in cancer immunology and treatments are continually being made, and there are so many rich areas where mathematical modeling can yield surprising and helpful insights.\u201d<\/p>\n\n\n\n

Further reading: There are currently several clinical trials underway evaluating MSCs as delivery vehicles. See, for example: Mesenchymal Stem Cells (MSC) for Ovarian Cancer<\/a>; Genetically Modified Mesenchymal Stem Cell Therapeutic Against Head and Neck Cancer<\/a>. Another recent paper delves more deeply into the biological and clinical side of the challenges with oncolytic virotherapy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

A collaboration between Lisette de Pillis, Norman F. Sprague Jr. Professor of Life Sciences and Professor of Mathematics at Harvey […]<\/p>\n","protected":false},"author":145,"featured_media":5406,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"class_list":["post-8124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/posts\/8124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/comments?post=8124"}],"version-history":[{"count":1,"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/posts\/8124\/revisions"}],"predecessor-version":[{"id":13004,"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/posts\/8124\/revisions\/13004"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/media\/5406"}],"wp:attachment":[{"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/media?parent=8124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hmc.edu\/about\/wp-json\/wp\/v2\/categories?post=8124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}